Azitra (AZTR) Total Liabilities (2022 - 2026)
Azitra (AZTR) posted Total Liabilities of $1.6 million for Q1 2026, up 34.5% on a QoQ basis from $1.2 million in Q4 2025, and up 9.75% year-over-year from $1.5 million in Q1 2025.
Azitra (AZTR) Total Liabilities (2022 - 2026) Analysis & Trends
Azitra's Total Liabilities history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Total Liabilities rose 9.75% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 9.75% YoY) and the FY2025 annual result came in at $1.2 million, down 26.28% from the prior year.
- Total Liabilities was $1.6 million for Q1 2026 at Azitra, up from $1.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $9.7 million in Q4 2022 and bottomed at $1.2 million in Q4 2025.
- A 5-year average of $2.5 million and a median of $1.7 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities plunged 77.37% — and 2025, when it increased 17.56%.
- Azitra's Total Liabilities stood at $9.7 million in 2022, then tumbled by 77.37% to $2.2 million in 2023, then dropped by 24.6% to $1.7 million in 2024, then declined by 26.28% to $1.2 million in 2025, then surged by 34.5% to $1.6 million in 2026.
- Business Quant data shows AZTR's Total Liabilities at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | 173.24 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 19.51 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 3.79 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 7.12 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 9.45 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | 15.48 Mn |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 1.62 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 4.05 Bn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 753.82 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.59 Mn |
| Dec 31, 2022 | 9.73 Mn |